AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Millendo Therapeutics to Present at the Stifel 2019 Healthcare Conference

November 11, 2019 GMT

ANN ARBOR, Mich.--(BUSINESS WIRE)--Nov 11, 2019--

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 9:45 a.m. EST.

A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191111005071/en/

CONTACT: Millendo Investor Contact:

Stephanie Ascher

Stern Investor Relations

212-362-1200

stephanie.ascher@sternir.com

Millendo Media Contact:

Julie Bane

MacDougall

617-821-1089

jbane@macbiocom.com

KEYWORD: MICHIGAN NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS

SOURCE: Millendo Therapeutics

Copyright Business Wire 2019.

PUB: 11/11/2019 08:30 AM/DISC: 11/11/2019 08:30 AM

http://www.businesswire.com/news/home/20191111005071/en